**Question:** Which of the following drug is effective against HIV with Y181C mutation?

A. Efavirenz
B. Ritonavir
C. Darunavir
D. Nelfinavir

**Core Concept:**
The question is testing our understanding of HIV drug resistance and its mutations. HIV-1 reverse transcriptase (RT) and protease (PR) enzymes have been widely used as targets for antiretroviral therapy (ART) drugs. Mutations in these enzymes can lead to drug resistance, reducing the effectiveness of these drugs. The Y181C mutation is a mutation in HIV-1 protease enzyme, which occurs when a tyrosine residue at position 181 is replaced by cysteine. This mutation can lead to resistance against certain drugs.

**Why the Correct Answer is Right:**
Among the given options, Darunavir is effective against HIV with Y181C mutation. Darunavir is a protease inhibitor (PI) antiretroviral drug that inhibits the HIV-1 protease enzyme, preventing the maturation of the virus and reducing viral replication. While the Y181C mutation does affect the enzyme, Darunavir still shows some level of activity against this mutation, making it the correct answer.

**Why Each Wrong Option is Incorrect:**

A. Efavirenz (EFV) is an NNRTI (non-nucleoside reverse transcriptase inhibitor) antiretroviral drug that inhibits the HIV-1 reverse transcriptase enzyme, preventing the conversion of viral RNA to DNA. However, EFV is not effective against Y181C mutation, making it the incorrect option.

B. Ritonavir (RTV) is a booster drug used primarily with protease inhibitors like Darunavir to increase their plasma concentrations. Although it does not directly target the Y181C mutation, it can enhance the activity of Darunavir against the mutation, making it less effective but not the correct answer.

C. Nelfinavir (NFV) is a protease inhibitor antiretroviral drug that inhibits the HIV-1 protease enzyme, preventing the maturation of the virus and reducing viral replication. The Y181C mutation affects the enzyme's activity, making NFV less effective against this mutation.

**Clinical Pearl:**
Understanding drug resistance and mutations in HIV is crucial in selecting appropriate antiretroviral therapy regimens for patients. This involves considering the specific mutation profile and matching the drug regimen to combat the mutations effectively. While Darunavir is effective against the Y181C mutation, it is essential to consider other mutations and patient factors such as renal function, drug interactions, and potential side effects when selecting the best treatment option.